Pretreatment HIV drug Resistance and Treatment Failure in Non-Italian HIV-1-Infected Patients Enrolled in ARCA. Issue 2 (February 2020)
- Record Type:
- Journal Article
- Title:
- Pretreatment HIV drug Resistance and Treatment Failure in Non-Italian HIV-1-Infected Patients Enrolled in ARCA. Issue 2 (February 2020)
- Main Title:
- Pretreatment HIV drug Resistance and Treatment Failure in Non-Italian HIV-1-Infected Patients Enrolled in ARCA
- Authors:
- Bavaro, Davide Fiore
Carlo, Domenico Di
Rossetti, Barbara
Bruzzone, Bianca
Vicenti, Ilaria
Pontali, Emanuele
Zoncada, Alessia
Lombardi, Francesca
Di Giambenedetto, Simona
Borghi, Vanni
Pecorari, Monica
Milini, Paola
Meraviglia, Paola
Monno, Laura
Saracino, Annalisa - Abstract:
- Background: An increase in pretreatment drug resistance (PDR) to first-line antiretroviral therapy (ART) in low-income countries has been recently described. Herein we analyse the prevalence of PDR and risk of virological failure (VF) over time among migrants to Italy enrolled in ARCA. Methods: HIV-1 sequences from ART-naive patients of non-Italian nationality were retrieved from ARCA database from 1998 to 2017. PDR was defined by at least one mutation from the reference 2009 WHO surveillance list. Results: Protease/reverse transcriptase sequences from 1, 155 patients, mainly migrants from sub-Saharan Africa (SSA; 42%), followed by Latin America (LA; 25%) and Western countries (WE; 21%), were included. PDR was detected in 8.6% of sequences (13.1% versus 5.8% for B and non-B strains, respectively; P <0.001), 2.1% of patients carried a PDR for protease inhibitors (PIs; 2.1% versus 2.3%; P =0.893), 3.9% for nucleoside/ nucleotide reverse transcriptase inhibitors (NRTIs; 6.8% versus 2.1%; P <0.001) and 4.3% for non-nucleoside/ nucleotide reverse transcriptase inhibitors (NNRTIs; 6.3% versus 3.1%; P =0.013). Overall, prevalence of PDR over the years remained stable, while it decreased for PIs in LA ( P =0.021) and for NRTIs ( P =0.020) among migrants from WE. Having more than one class of PDR ( P =0.015 versus absence of PDR), higher viral load at diagnosis ( P =0.008) and being migrants from SSA ( P =0.001 versus WE) were predictive of VF, while a recent calendar year ofBackground: An increase in pretreatment drug resistance (PDR) to first-line antiretroviral therapy (ART) in low-income countries has been recently described. Herein we analyse the prevalence of PDR and risk of virological failure (VF) over time among migrants to Italy enrolled in ARCA. Methods: HIV-1 sequences from ART-naive patients of non-Italian nationality were retrieved from ARCA database from 1998 to 2017. PDR was defined by at least one mutation from the reference 2009 WHO surveillance list. Results: Protease/reverse transcriptase sequences from 1, 155 patients, mainly migrants from sub-Saharan Africa (SSA; 42%), followed by Latin America (LA; 25%) and Western countries (WE; 21%), were included. PDR was detected in 8.6% of sequences (13.1% versus 5.8% for B and non-B strains, respectively; P <0.001), 2.1% of patients carried a PDR for protease inhibitors (PIs; 2.1% versus 2.3%; P =0.893), 3.9% for nucleoside/ nucleotide reverse transcriptase inhibitors (NRTIs; 6.8% versus 2.1%; P <0.001) and 4.3% for non-nucleoside/ nucleotide reverse transcriptase inhibitors (NNRTIs; 6.3% versus 3.1%; P =0.013). Overall, prevalence of PDR over the years remained stable, while it decreased for PIs in LA ( P =0.021) and for NRTIs ( P =0.020) among migrants from WE. Having more than one class of PDR ( P =0.015 versus absence of PDR), higher viral load at diagnosis ( P =0.008) and being migrants from SSA ( P =0.001 versus WE) were predictive of VF, while a recent calendar year of diagnosis ( P <0.001) was protective for VF. Conclusions: PDR appeared to be stable over the years in migrants to Italy enrolled in ARCA; however, it still remains an important cause of VF together with viral load at diagnosis. … (more)
- Is Part Of:
- Antiviral therapy. Volume 25:Issue 2(2020)
- Journal:
- Antiviral therapy
- Issue:
- Volume 25:Issue 2(2020)
- Issue Display:
- Volume 25, Issue 2 (2020)
- Year:
- 2020
- Volume:
- 25
- Issue:
- 2
- Issue Sort Value:
- 2020-0025-0002-0000
- Page Start:
- 61
- Page End:
- 71
- Publication Date:
- 2020-02
- Subjects:
- Antiviral agents -- Periodicals
Antiviral Agents -- therapeutic use
Virus Diseases -- therapy
Viruses -- drug effects
Antiviral agents
Periodical
Electronic journals
Periodicals
616.9106 - Journal URLs:
- http://www.intmedpress.com/General/showSectionSub.cfm?SectionID=2&SectionSubID=1&SectionSubSubID=1 ↗
http://www.uk.sagepub.com/home.nav ↗ - DOI:
- 10.3851/IMP3349 ↗
- Languages:
- English
- ISSNs:
- 1359-6535
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 17215.xml